Exogenous thyroxine improves glucose intolerance in insulin-resistant rats

1. View larger version:

   • In this window
   • In a new window

   • Download as PowerPoint Slide

   Figure 1

   Mean (±s.e.) (A) food consumption, (B) BM throughout the course of the study and (C) cumulative change of BM of LETO, OLETF and OLETF+T₄. ^†P < 0.05 vs LETO.
2. View larger version:

   • In this window
   • In a new window

   • Download as PowerPoint Slide

   Figure 2

   Mean (±s.e.) (A) blood glucose and (B) plasma insulin levels taken during an oral glucose tolerance test and corresponding area under the curve (AUC) and (C) insulin resistance index (IRI) of LETO, OLETF and OLETF + T₄. ^†P < 0.05 vs LETO. ^#P < 0.05 vs OLETF.
3. View larger version:

   • In this window
   • In a new window

   • Download as PowerPoint Slide

   Figure 3

   Mean (±s.e.) (A) TSH, (B) total T₄, (C) free T₄ (fT4) and (D) total T₃ measured in plasma of LETO, OLETF and OLETF + T₄. ^†P < 0.05 vs LETO. ^#P < 0.05 vs OLETF.
4. View larger version:

   • In this window
   • In a new window

   • Download as PowerPoint Slide

   Figure 4

   Mean (±s.e.) percent change from LETO for Na+/K+ ATPase in soleus muscle of LETO, OLETF and OLETF + T₄ after 5-week treatment and representative Western blot bands. ^†P < 0.05 vs LETO. ^#P < 0.05 vs OLETF.
5. View larger version:

   • In this window
   • In a new window

   • Download as PowerPoint Slide

   Figure 5

   Mean (±s.e.) fold change of mRNA expression relative to LETO for (A) Mct10, (B) DI1, (C) Di2, (D) THRβ-1, (E) Ucp2 and (F) SIRT 1 in soleus muscle of LETO, OELTF and OLETF + T₄ after 5-week treatment. ^†P < 0.05 vs LETO. ^#P < 0.05 vs OLETF.
6. View larger version:

   • In this window
   • In a new window

   • Download as PowerPoint Slide

   Figure 6

   Mean (±s.e.) percent change from LETO for the ratios of (A) p-INS to INS (B) p-AMPK to AMPK including representative Western blot bands and (C) mean fold-change of mRNA expression relative to LETO for Glut4 in soleus muscle of LETO, OLETF and OLETF + T₄ after 5-week treatment. ^#P < 0.05 vs OLETF.

• © 2017 Society for Endocrinology